Rebekah Puls

Does Choice of Combination Antiretroviral Therapy (cART) Alter Changes in Cerebral Function Testing after 48 Weeks in Treatment‐Naive, HIV‐1–Infected Individuals Commencing cART? A Randomized, Controlled Study

Alan Winston, Chris Duncombe, Patrick CK Li et al. · Clinical Infectious Diseases · 2010 · 103 citations · Full text

Medicine, Neurology, Pharmacology +17

Pharmacokinetic and Pharmacodynamic Comparison of Once‐Daily Efavirenz (400 mg vs. 600 mg) in Treatment‐Naïve HIV‐Infected Patients: Results of the ENCORE1 Study

Laura Dickinson, Janaki Amin, Laura Else et al. · Clinical Pharmacology & Therapeutics · 2015 · 74 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

A randomized, placebo-controlled phase I trial of DNA prime, recombinant fowlpox virus boost prophylactic vaccine for HIV-1

Anthony D. Kelleher, Rebekah Puls, Mark Bebbington et al. · AIDS · 2006 · 65 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17

Efavirenz versus Boosted Atazanavir or Zidovudine and Abacavir in Antiretroviral Treatment–Naive, HIV‐Infected Subjects: Week 48 Data from the Altair Study

Rebekah Puls, Preeyaporn Srasuebkul, Kathy Petoumenos et al. · Clinical Infectious Diseases · 2010 · 60 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naïve HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 Study

Laura Dickinson, Janaki Amin, Laura Else et al. · Clinical Pharmacokinetics · 2015 · 51 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17